Vir Biotechnology posts Q2 net income of $80.1 million on $240 million Astellas payment
Vir Biotechnology reported second quarter 2026 net income of $80.1 million, or $0.47 per diluted share, versus a net loss of $111.0 million a year earlier, driven by $238.9 million of license and collaboration revenue tied to the closed Astellas collaboration. Cash, cash equivalents and investments were about $1.01 billion at June 30, 2026, and the company expects that cash to fund operations into the second half of 2028.
Key points
- Total revenues were $238.9 million in the quarter, versus $1.2 million a year earlier, mainly from the $240.0 million Astellas upfront payment.
- Research and development expenses rose to $135.3 million from $97.5 million, including a $48.0 million milestone payment to Sanofi.
- Cash, cash equivalents and investments were about $1.01 billion at June 30, 2026, up about $198.5 million in the quarter.
- Topline data from Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.